|
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix Clinical research trials and Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix. Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix  Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
For Condition: recurrent cervical cancer,stage 4A cervical cancer,stage 4B cervical cancer,cervical squamous cell carcinoma
Status: Suspended
Sponsor(s): National Cancer Institute (NCI) , Gynecologic Oncology Group
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and cisplatin in treating patients who have refractory or recurrent cancer of the cervix.
Details: OBJECTIVES: I. Determine the antitumor activity of gemcitabine and cisplatin in patients with refractory or recurrent squamous cell carcinoma of the cervix. II. Determine the nature and degree of toxicity of this regimen in these patients. PROTOCOL OUTLINE: This is a multicenter study. Patients receive cisplatin IV and gemcitabine IV over 1 hour on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 28-69 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed refractory or recurrent squamous cell carcinoma of the cervix that has failed local therapy and is considered incurable - Must have had 1 prior chemotherapy regimen for cervical cancer; No more than 1 prior chemotherapy regimen (single or combination drug therapy), unless used as a radiosensitizer; No prior chemotherapy for recurrent or persistent disease including retreatment with initial chemotherapy - Bidimensionally measurable disease - Ineligible for higher priority GOG protocol --Prior/Concurrent Therapy-- - Biologic therapy: At least 3 weeks since prior biologic therapy for cervical cancer - Chemotherapy: See Disease Characteristics; At least 3 weeks since prior chemotherapy for cervical cancer and recovered; No prior gemcitabine - Endocrine therapy: At least 3 weeks since prior endocrine therapy for cervical cancer - Radiotherapy: At least 3 weeks since prior radiotherapy for cervical cancer and recovered; No prior radiotherapy to more than 25% of marrow-bearing areas - Surgery: At least 3 weeks since prior surgery for cervical cancer and recovered - Other: No concurrent amifostine or other protective reagents; No prior anticancer therapy that contraindicates study --Patient Characteristics-- - Age: Not specified - Performance status: GOG 0-2 - Life expectancy: Not specified - Hematopoietic: Platelet count at least lower limit of normal; Absolute neutrophil count at least 1,500/mm3 - Hepatic: Bilirubin no greater than 1.5 times normal; SGOT and alkaline phosphatase no greater than 3 times normal - Renal: Creatinine no greater than 2.0 mg/dL - Other: Not pregnant; Fertile patients must use effective contraception; No significant infection; No other malignancies within past 5 years except nonmelanoma skin cancer
Total Enrollment:
Location and Contact Information:
Overall Study Official:
CherylBrewer, Study Chair, Gynecologic Oncology Group
Schneider Children's Hospital at North Shore
Manhasset, New York, 11030
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289
United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
United States
Abington Memorial Hospital
Abington, Pennsylvania, 19001
United States
Community Hospital of Los Gatos
Los Gatos, California, 95032
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104-4283
United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45267-0502
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Tufts University School of Medicine
Boston, Massachusetts, 02111
United States
Cooper Hospital/University Medical Center
Camden, New Jersey, 08103
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
United States
Cancer Center at the University of Virginia
Charlottesville, Virginia, 22908
United States
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma, 73190
United States
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Canada
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
United States
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
Rational Therapeutics Inc.
Long Beach, California, 90807
United States
Tacoma General Hospital
Tacoma, Washington, 98405
United States
Rush-Presbyterian-St. Luke's Medical Center
Chicago, Illinois, 60612
United States
Cancer Center of Albany Medical Center
Albany, New York, 12208
United States
Comprehensive Cancer Center at Wake Forest University
Winston Salem, North Carolina, 27157-1082
United States
University of Illinois College of Medicine at Peoria
Peoria, Illinois, 61603
United States
Additional Information:
Study ID Numbers: CDR0000068313; GOG-0127Q
Study Start Date: January 2001
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006482
Other Stage 4b Cervical Cancer Studies:
1. Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
2. Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
3. Comparison of Cisplatin Combined With Either Paclitaxel or Gemcitabine in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
4. Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
5. Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
Related Studies:
Other stage 4B cervical cancer Clinical Trials
Other Illinois Clinical Trials
Other Peoria Clinical Trials
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
|
|
|
|
|
|
|
|
